Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of alternative manufacturing process MMRV vaccine versus ProQuad in children 12 to 23 months old
2017-001443-13Phase 3
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in measles, mumps, rubella and 1 more comparing MMRV vaccine (alternative manufacturing process) with ProQuad (2006 process) (2 arms). Primary endpoints: Measles antibody response rate at 6 weeks postdose 1, Mumps antibody response rate at 6 weeks postdose 1 and 2 more.
02
Drugs
varicella virus vaccinemeasles + mumps + rubella + varicella virus vaccine live
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2017-001443-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001443-13.